INO Share Price | Inovio Pharmaceuticals, Inc. Stock Analysis & Recommendation

Q: What does Inovio Pharmaceuticals, Inc. do?

Overview: Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company focused on developing DNA immunotherapies and vaccines for treating and preventing cancers and infectious diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -20 Million (Quarterly Results - Mar 2025) Market-cap: USD 69.68 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.28 Return on Equity: -204.32% Price to Book: 1.36Contact Details: Address: 6769 Mesa Ridge Rd, SAN DIEGO CA: 92121-2995 Tel: 1 858 4103134 Fax: 1 858 4041392 Website: http://www.inovio.com/

Q: Is Inovio Pharmaceuticals, Inc. overvalued or undervalued?

As of 9 November 2023, Inovio Pharmaceuticals, Inc. has seen its valuation grade change from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently overvalued, as reflected by its Price to Book Value of 1.62 and negative ratios such as EV to EBIT at -0.16 and EV to EBITDA at -0.17. Additionally, the Return on Equity (ROE) stands at a staggering -204.32%, highlighting severe inefficiencies and losses.When compared to peers, Inovio's valuation metrics are concerning. For instance, Mind Medicine (MindMed), Inc. and Talaris Therapeutics, Inc. also do not qualify, with EV to EBITDA ratios of -2.78 and -2.21, respectively, indicating similar struggles within the sector. Despite a year-to-date return of 5.46%, which is better than the S&P 500's 2.44%, the long-term performance is alarming, with a 1-year decline of 76.14% and a staggering 99.25% drop over the past five years. This further reinforces the conclusion that Inovio Pharmaceuticals is currently overvalued.

Q: Is Inovio Pharmaceuticals, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for Inovio Pharmaceuticals, Inc. has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed indicators. The weekly MACD and Dow Theory are mildly bullish, while the daily moving averages are mildly bearish. The monthly RSI shows bullish momentum, but Bollinger Bands indicate a bearish trend. In terms of returns, the stock has underperformed the S&P 500 over the past year and three years, with a -65.88% return compared to the S&P 500's 17.14%, and a staggering -90.03% over three years versus the S&P 500's 70.41%.

Results Declared: Inovio Pharmaceuticals, Inc. has declared results on 12 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

124.37 k

Shareholding (Dec 2025)

FII

2.54%

Held by 42 FIIs

DII

75.04%

Held by 26 DIIs

Promoter

0.11%

How big is Inovio Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Inovio Pharmaceuticals, Inc. has a market capitalization of 69.68 million, with net sales of 0.29 million and a net profit of -96.48 million over the latest four quarters. Shareholder's funds are reported at 68.50 million, and total assets amount to 114.90 million.

View full answer

What does Inovio Pharmaceuticals, Inc. do?

22-Jun-2025

Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company focused on developing DNA immunotherapies and vaccines for cancer and infectious diseases. As of March 2025, it has a market cap of $69.68 million, with net sales of $0 and a net loss of $20 million.

View full answer

Who are in the management team of Inovio Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Inovio Pharmaceuticals, Inc. includes Mr. Simon Benito (Independent Chairman), Dr. Jong Kim (CEO), Dr. David Weiner, Dr. Ann Miller, Mr. Jay Shepard, Ms. Wendy Yarno, and Ms. Lota Zoth (all Independent Directors). They oversee the company's strategic direction and operations.

View full answer

Is Inovio Pharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

As of November 9, 2023, Inovio Pharmaceuticals, Inc. is considered overvalued with a valuation grade change to "does not qualify," marked by a Price to Book Value of 1.62, negative EV to EBIT and EV to EBITDA ratios, and a Return on Equity of -204.32%, alongside a troubling long-term performance decline of 99.25% over five years.

View full answer

Is Inovio Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Inovio Pharmaceuticals' technical trend is neutral with mixed indicators, showing a shift from mildly bullish to sideways, and it has significantly underperformed the S&P 500 with returns of -65.88% over the past year and -90.03% over three years.

View full answer

Compare Inovio Pharmaceuticals, Inc. with Similar Stocks

Reviva Pharmaceuticals Holdings, Inc.Nektar Therapeutics Talaris Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 113 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

6.23

Return on Equity

1,186.42%

Price to Book

-14.59

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

4 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-31.56%

6 Months

-38.89%

1 Year

-18.09%

2 Years

-86.75%

3 Years

60.0%

4 Years

-59.04%

5 Years

-98.57%

Inovio Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-38.88%

EBIT Growth (5y)

5.11%

EBIT to Interest (avg)

-110.14

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.28

Sales to Capital Employed (avg)

0.01

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

56.17%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-14.59

EV to EBIT

-0.72

EV to EBITDA

-0.74

EV to Capital Employed

-1.16

EV to Sales

64.56

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 19 Schemes (22.31%)

Foreign Institutions

Held by 42 Foreign Institutions (2.54%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 108.35% vs -93.62% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-16.70",
          "val2": "-20.50",
          "chgp": "18.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "21.20",
          "val2": "-22.30",
          "chgp": "195.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "3.80",
          "val2": "-45.50",
          "chgp": "108.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -50.00% vs -75.00% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 20.88% vs 20.58% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.20",
          "chgp": "-50.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-83.80",
          "val2": "-110.90",
          "chgp": "24.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.20",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.60",
          "val2": "4.90",
          "chgp": "-67.35%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-84.90",
          "val2": "-107.30",
          "chgp": "20.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,328,713.20%",
          "val2": "-523,516.80%",
          "chgp": "-80,519.64%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-16.70

-20.50

18.54%

Interest

0.00

Exceptional Items

21.20

-22.30

195.07%

Consolidate Net Profit

3.80

-45.50

108.35%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 108.35% vs -93.62% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.10

0.20

-50.00%

Operating Profit (PBDIT) excl Other Income

-83.80

-110.90

24.44%

Interest

0.00

0.20

-100.00%

Exceptional Items

1.60

4.90

-67.35%

Consolidate Net Profit

-84.90

-107.30

20.88%

Operating Profit Margin (Excl OI)

-1,328,713.20%

-523,516.80%

-80,519.64%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is -50.00% vs -75.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 20.88% vs 20.58% in Dec 2024

All Annual Results

Company CV

About Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Company Coordinates

Company Details

6769 Mesa Ridge Rd , SAN DIEGO CA : 92121-2995

Tel: 1 858 4103134

http://www.inovio.com/

Registrar Details